The anticancer activity of siRNA targeting anti-apoptotic genes, including Mcl-1, Bcl-2, and survivin, without chemotherapeutic drug treatment, were first screened against breast cancer cell lines to identify attractive genes which may be combined with existing chemotherapeutic agents to increase anticancer effects. This evidence concerns the gene MCL1 and breast carcinoma.